Exploring HER2 Detection in Ovarian Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the detection of HER2 in patients with high-grade serous adenocarcinoma of the ovary. It aims to establish diagnostic criteria and positive thresholds for HER2 expression, which is crucial for the effectiveness of targeted antibody drug conjugates (ADCs). The study will analyze existing pathological samples to gather data on HER2 expression rates and their implications for treatment outcomes. By addressing the current lack of large-scale data and clear detection standards, the study seeks to improve clinical practices in managing ovarian cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathological type: high-grade serous adenocarcinoma of the ovary
2. Pathological slices stored within 5 years
3. FIGO stage II or above
4. Complete clinical and follow-up data

Exclusion Criteria:

1. Slice quality control failure
2. Incomplete follow-up data

Where it's running

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  Guangzhou, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• First-line combo therapy with anlotinib, benmelstobart, and HAIC for unresectable HCC

  This study tests whether adding benmelstobart and hepatic arterial infusion chemotherapy to anlotinib can help people with unresectable hepatocellular carcinoma respond to treatment as a first line.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07806292

• Culmerciclib with endocrine therapy before surgery for early HER2-negative hormone receptor-positive breast cancer

  This trial tests whether adding culmerciclib to an aromatase inhibitor before surgery helps women with certain early breast cancers better shrink tumors than an aromatase inhibitor alone.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07796880

• Optical surface guidance for head and neck radiotherapy with open-face mask

  This trial tests whether using optical surface guidance with an open-face mask during radiotherapy for head and neck cancer improves positioning and reduces movement compared with the standard closed mask approach.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07726407

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.